• by Nina Lentini  @Nina_Lentini, May 23, 2007

In the drug treatment market for asthma, the launch of Schering-Plough/Novartis' indacaterol/mometasone is not likely to displace market leader Advair/Seretide from GlaxoSmithKline, a report from Decision Resources finds.

According to the new Pharmacor report titled "Asthma," the launch of the once-daily emerging therapy indacaterol/mometasone--estimated to achieve blockbuster status in 2016--will not displace Advair/Seretide, the current market leader, which generated sales of more than $3 billion in 2006 in the world's major pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan).

Despite the future blockbuster status of several drugs, the increased cost-consciousness in many markets combined with the impending arrival of multiple lower-priced emerging therapies will result in only modest annual growth in the asthma market from 2006 to 2011, and a small decline in its growth between 2011 and 2016.

The report also finds that the emerging biologic agents Amgen/Wyeth/Takeda's Enbrel, Centocor/Schering-Plough/Tanabe/Janssen Pharmaceuticals' golimumab, Abbott/Eisai's Humira, and PDL BioPharma's Zenapax will generate $785 million in sales in 2016.

"These high-priced emerging biologics will generate significant major market sales despite the small eligible patient population that will receive such agents--severe asthmatics who do not respond to conventional therapy," said Madhuri Borde, Ph.D., analyst at Decision Resources, via a press release.